United Capital Financial Advisors LLC Acquires Shares of 70,682 Immix Biopharma, Inc. $IMMX

United Capital Financial Advisors LLC acquired a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 70,682 shares of the company’s stock, valued at approximately $729,000.

Other hedge funds have also recently modified their holdings of the company. Allworth Financial LP purchased a new position in Immix Biopharma during the fourth quarter valued at $30,000. Legal & General Group Plc bought a new stake in Immix Biopharma in the 2nd quarter valued at $41,000. Mathes Company Inc. purchased a new stake in Immix Biopharma in the 4th quarter worth $56,000. Compass Financial Management LLC bought a new position in shares of Immix Biopharma during the 2nd quarter valued at about $56,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Immix Biopharma during the 4th quarter valued at about $67,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

Shares of IMMX opened at $13.94 on Monday. The firm has a fifty day moving average price of $10.62 and a 200-day moving average price of $9.56. The firm has a market capitalization of $997.25 million, a P/E ratio of -15.84 and a beta of 0.11. Immix Biopharma, Inc. has a 12-month low of $1.94 and a 12-month high of $15.10.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Analysts predict that Immix Biopharma, Inc. will post -0.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on IMMX shares. HC Wainwright lifted their target price on Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Citigroup restated a “market outperform” rating on shares of Immix Biopharma in a report on Friday, August 14th. Needham & Company LLC began coverage on Immix Biopharma in a research note on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Friday, July 17th. Finally, Lifesci Capital initiated coverage on Immix Biopharma in a research report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 target price for the company. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.29.

Immix Biopharma Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.